Metabolic myopathies

Current Rheumatology Reports

Volumn 12, Issue 5, 2010, Pages 386-393

  DiMauro, Salvatore ^a   Garone, Caterina ^a   Naini, Ali ^a  

^a Columbia University Medical Center ^*  (United States)

Author keywords

Aglycogenosis; Glycogenoses; Lipid storage myopathies; Mitochondrial myopathies

Indexed keywords

BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE; GLYCOGEN SYNTHASE; GLYCOGENIN; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOGLUCOMUTASE; PROSTAGLANDIN SYNTHASE; PROTEIN MELAS; PROTEIN NDUFS1; TRANSFER RNA; UBIDECARENONE; UNCLASSIFIED DRUG;

APOPTOSIS; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CHRONIC FATIGUE SYNDROME; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; ENZYME ACTIVITY; FIBROMYALGIA; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOSYLATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPID METABOLISM; LIPID STORAGE MYELOPATHY; MELAS SYNDROME; METABOLIC DISORDER; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MUSCLE ATROPHY; NONHUMAN; NONSENSE MUTATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

ANIMALS; CELL NUCLEUS; DNA; DNA, MITOCHONDRIAL; FATTY ACIDS; GLYCOGEN; HUMANS; LIPID METABOLISM; METABOLISM, INBORN ERRORS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL MYOPATHIES; MUSCULAR DISEASES; MUTATION;

EID: 78149465126     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0119-9     Document Type: Review

References (49)

1. Kollberg G, Tulinius M, Gilljam T, et al.: Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 2007, 357:1507-1514.
2. McCue ME, Valberg SJ, Miller MB, et al.: Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis. Genomics 2008, 91:458-466.
3. Pitcher J, Smythe C, Cohen P: Glycogenin is the priming glucosyltransferase required for the initiation of glycogen biogenesis in rabbit skeletal muscle. Eur J Biochem 1988, 176:391-395.
4. •• Moslemi A-R, Lindberg C, Nilsson J, et al.: Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N Engl J Med 2010, 362:1203-1210. These are the long-awaited first mutations in the muscle glycogenin gene and the second example of "glycogenosis 0" in human muscle.
5. •• Stojkovic T, Vissing J, Petit F, et al.: Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med 2009, 361:425- 427. This is a new glycolytic defect showing the "typical" syndrome of exercise intolerance, cramps, and recurrent myoglobinuria.
6. Sugie H, Kobayashi J, Sugie Y, et al.: Infantile muscle glycogen storage disease: phosphoglucomutase deficiency with decreased muscle and serum carnitine. Neurology 1988, 38:602-605.
7. Nadaj-PaklezaAA, Vincitorio CM, Laforet P, et al.: Permanentmuscle weakness in McArdle disease. Muscle Nerve 2009, 40:350-357.
8. • Vissing J, Duno M, Schwartz M, Haller RG: Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Brain 2009, 132:1545-1552. This is an interesting genotype-phenotype association documenting that even a very small amount of residual enzyme activity ameliorates the clinical presentation.
9. Orngreen MC, Jeppesen TD, Tvede Andersen S, et al.: Fat metabolism during exercise in patients with McArdle diseae. Neurology 2009, 72:718-724.
10. Quinlivan R, Beynon RJ: Pharmacological and nutritional treatment for McArdle's disease (glycogen storage disease type V). Cochrane Database Syst Rev 2004, 3:CD003458.
11. • van der Ploeg AT, Clemens PR, Corzo D, et al.: A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010, 362:1396-1406. This is the first (but probably not the last) multicentric study of enzyme replacement therapy in glycogenosis type II.
12. Kishnani PS, Goldenberg PC, DeArmey SL, et al.: Cross-reacting immunological material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010, 99:26-33.
13. Mendelsohn NJ, Messinger YH, Rosenberg A, Kishnani P: Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 2009, 360:194-195.
14. Parenti G: Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009, 1:268-279.
15. • Ramachandran N, Girard J-M, Turnbull J, Minassian B: The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia 2009, 50(Suppl 5):29-36. This is an excellent critical review of Lafora's disease and other progressive myoclonic epilepsies.
16. • Ohkuma A, Noguchi S, Sugie H, et al.: Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009, 39:333-342. This is an excellent systematic analysis of a large cohort of patients with LSM and a critical review of the subject.
17. el-Hattab AW, Li F-Y, Shen J, et al.: Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010, 12:19-24.
18. • Bruno C, Bertini E, Di Rocco M, et al.: Clinical and genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Comm 2008, 369:1125-1128. This is an excellent review of Chanarin-Dorfman syndrome.
19. •• Akman HO, Davidzon G, Tanji K, et al.: Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscul Disord 2010, 20:397-402. This article discussed an interesting presymptomatic patient with an unusual mutation and a problematic disconnect between muscle biopsy and normal strength.
20. Gempel K, Topaloglu H, Talim B, et al.: The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electrontransferring- flavoprotein dehydrogenase (ETFDH) gene. Brain 2007, 130:2037-2044.
21. Liang W-C, Ohkuma A, Hayashi YK, et al.: ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord 2009, 19:212-216.
22. • Bonnefont J-P, Bastin J, Behin A, Djouadi F: Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009, 360:838-840. This article discusses a convincing and promising therapeutic approach to an inborn error of metabolism.
23. Roe CR, Yang B-Z, Brunengraber H, et al.: Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008, 71:260-264.
24. Schaefer AM, McFarland R, Blakely E, et al.: Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008, 63:35-39.
25. •• Elliott HR, Samuels DC, Eden JA, et al.: Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008, 83:254-260. This article presented astonishing results of a simple but long overdue survey of healthy newborns showing an unexpectedly high prevalence of mtDNA pathogenic mutations.
26. • Kaufmann P, Engelstad K, Wei Y, et al.: Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol 2009, 66:85-91. This study provided interesting documentation of the clinical spectrum of the common MELAS mutation in a large cohort of mutation carriers.
27. • Davidson MM, Walker WF, Hernandez-Rosa E: The m.3243A>G mtDNA mutation is pathogenic in an in vitro model of the human blood brain barrier. Mitochondrion 2009, 9:463-470. This article presented elegant in vitro modeling of the human BBB and a promising tool for studies of pathogenesis and therapeutic strategies.
28. •• Horvath R, Kemp JP, Tuppen HAL, et al.: Molecular basis of infantile reversible cytochrome c oxidase deficiency. Brain 2009, 132:3165-3174. This was a fascinating example of the complex interaction between the nuclear and mitochondrial genomes.
29. Hoefs SJG, Skjeldal OH, Rodenburg RJ, et al.: Novel mutations in the NDUFS1 gene cause low residual activities in human complex I deficiencies. Mol Gen Metab 2010, 100:251-256.
30. Lagier-Tourenne C, Tazir M, Lopez LC, et al.: ADSK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008, 82:661-672.
31. Mollet J, Delahodde A, Serre V, et al.: CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 2008, 82:623-630.
32. Duncan AJ, Bitner-Glindziez M, Meunier B, et al.: A nonsense mutation in COQ9 causes autosomal recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet 2009, 84:558-566.
33. • Sacconi S, Trevisson E, Salviati L, et al.: Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010, 20:44-48. This was an interesting collaborative study documenting secondary CoQ10 deficiency in patients with primary mitochondrial myopathy.
34. Cordero MD, Moreno-Fernandez AM, deMiguel M, et al.: Coenzyme Q10 distribution is altered in patients with fibromyalgia. Clin Biochem 2009, 42:732-735.
35. •• Massa V, Fernandez-Vizarra E, Alshahwan S, et al.: Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am J Hum Genet 2008, 82:1281-1289. This study was a historical "first" showing that mutations affecting COX subunits directly do occur.
36. Sugiana C, Pagliarini DJ, McKenzie M, et al.: Mutation of C20orf7 disrupts complex I assembly and causes lethal neonatal mitochondrial disease. Am J Hum Genet 2008, 83:468-478.
37. Saada A, Edvardson S, Rapaport M, et al.: C6ORF66 is an assembly factor of mitochondrial complex I. Am J Hum Genet 2008, 82:32-38.
38. •• Weraarpachai W, Antonicka H, Sasarman F, et al.: Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset Leigh syndrome. Nat Genet 2009, 41:833-837. This was the first demonstration that "indirect hits" can affect isolated subunits of RC complexes.
39. Cizkova A, Stranecky V, Mayr JA, et al.: TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalomyopathy. Nat Genet 2009, 40:1288-1290.
40. •• Yu-Wai-Man P, Griffiths PG, Gorman GS, et al.: Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010, 133:771-786. This was an important demonstration of the protean phenotypic expression of OPA1 mutations.
41. • Smits P, Smeitink JAM, van den Heuvel B: Mitochondrial translation and beyond: processes implicated in combined oxidative phosphorylation deficiencies. J Biomed Biotechnol 2010 Apr 13 (Epub ahead of print). This is a comprehensive and comprehensible review of a complex subject.
42. • Chen H, Chan DC: Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009, 18:R169-R176. This is a lucid review of mitochondrial dynamics gone awry.
43. Muller-Hocker J: Mitochondria and ageing. Brain Pathol 1992, 2:149-158.
44. •• Wenz T, Diaz F, Spiegelman BM, Moraes CT: Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008, 8:249-255. This is an elegant demonstration of how enhancing mitochondrial biogenesis can benefit an RC defect.
45. Wenz T, Rossi S, Rotundo RL, et al.: Increased muscle PGC- 1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 2009, 106:20405-20410.
46. • Wenz T, Diaz F, Hernandez D, Moraes CT: Endurance exercise is protective for mice with mitochondrial myopathy. J Appl Physiol 2009, 106:1712-1719. This article explains why aerobic exercise is beneficial in mitochondrial myopathies.
47. Civitarese AE, Carling S, Heilbronn LK, et al.: Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 2007, 4:e76.
48. Mathew SS, Mao X, Keegan KA, et al.: Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T 1H MRS imaging study. NMR Biomed 2009; 22:251-258.
49. Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2:1-16.